Sanofi and Evotec are in talks to create an infectious disease research center in Lyon, France, that is open to outside groups. Under the proposed deal, Sanofi’s early-stage infectious disease portfolio and 100 researchers will be folded into Evotec, which will get nearly $75 million and other “significant, long-term funding” from Sanofi. The French firm is keeping its vaccine activities and retains an option to license back certain anti-infective drugs. In 2015, Evotec took over Sanofi’s small-molecule drug development site in Toulouse, France, taking on more than 200 chemists. Sanofi paid the contract research firm $275 million over five years.